ArticleWorld journal of gastrointestinal surgery2026
Predictors of mortality and liver transplant requirement in patients with hepatitis A virus: A case series from Mexico.
Article in World journal of gastrointestinal surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis A virus (HAV) infection remains a significant cause of acute viral hepatitis globally, and the endemicity pattern is intermediate in Mexico. Although most cases follow a benign and self-limited course, less than 5% of patients with HAV infection progress to acute liver failure, which carries mortality rates of 13%-33% depending on access to liver transplantation (LT). The identification of clinical and biochemical predictors of adverse outcomes is crucial to improve early risk stratification, optimize patient management, and guide timely referral to transplant centers.
aimTo assess the utility of clinical and biochemical variables and prognostic scores in predicting mortality and the need for LT in patients with acute HAV infection.
methodsWe conducted a retrospective case series of all patients hospitalized at Medica Sur Clinic between 2018 and 2024 who were positive for immunoglobulin M antibodies for HAV. Clinical and laboratory data were collected from patients' electronic medical records. Continuous variables were summarized as the means ± SD or median and interquartile range and compared using Student's
resultsA total of 69 patients with HAV infection (mean age, 38 ± 11 years; 65% male) were included. 14% of patients had a history of hepatic steatosis, 10% had type 2 diabetes, and 45% were smokers. Acute liver injury was observed in 47 patients (68%), acute liver failure was detected in five patients (7.2%), and mortality or LT occurred in three patients (4.3%; two deaths and one transplant). Patients who died or required orthotopic LT were older, and they had higher heart and respiratory rates at admission. These patients additionally exhibited greater liver dysfunction, including higher bilirubin and transaminase levels, prolonged coagulation times, lower sodium and albumin levels, and worse albumin-bilirubin scores. Severity scores [model for end-stage liver disease (MELD), MELD with sodium, MELD version 3.0] were significantly higher in patients with complications than in those without complications.
conclusionAdvanced age, elevated severity, and higher albumin-bilirubin scores emerged as predictors of adverse outcomes in patients with HAV infection, and consideration of these factors could guide the need for more intensive monitoring strategies. These findings highlight the importance of incorporating prognostic scoring systems into routine clinical evaluation to improve outcomes in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.